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Proteinuria in rats induced by serum from patients with collaps-
ing glomerulopathy.
Background. Primary collapsing glomerulopathy recurs pos-
transplant, raising the possibility of circulating factors impli-
cated in the pathogenesis of the disease.
Methods. To determine the presence of circulating factors
in collapsing glomerulopathy patients, we tested serum from
those patients in an in vivo assay. Eleven groups of rats received
serum from collapsing glomerulopathy patients, idiopathic fo-
cal segmental glomerulosclerosis (FSGS) or healthy subjects in
its native form, isolated IgG, or serum without IgG. The pres-
ence of proteinuria and creatinine clearance were determined.
Histopathologic analysis included light, immunofluorescence,
and electron microscopy.
Results. Collapsing glomerulopathy rats developed protein-
uria while rats injected with serum from FSGS and healthy
subjects did not. Rats injected with serum of collapsing glomeru-
lopathy in its native form developed marked proteinuria (99.2 ±
42 mg/24 hours at day 5, P = 0.0001, compared to the baseline),
and decreased in creatinine clearance. Rats receiving isolated
IgG or serum without IgG from collapsing glomerulopathy de-
veloped mild proteinuria (46.5 ± 8.4 mg/24 hours and 30.9 ±
11 mg/24 hours, respectively, at day 5 (P = 0.0001). Glomerular
tuft retraction and podocyte damage were seen only in collaps-
ing glomerulapthy rats. No abnormalities were found in rats
injected with serum from FSGS or healthy subjects.
Conclusion. Circulating factors in the serum of collapsing
glomerulopathy patients produce podocyte damage, whereas
such factors are not present in noncollapsing FSGS. IgG eluates
from collapsing glomerulopathy produce proteinuria when in-
jected into the rat. Such factors remain in the circulation when
serum of patients is adsorbed into protein A, raising the possi-
bility that there are more than one circulating factor present in
patients with collapsing glomerulopathy.
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Collapsing glomerulopathy is an aggressive form of
glomerular damage characterized by heavy proteinuria,
renal insufficiency, and rapid progression to end-stage re-
nal disease (ESRD) [1]. Collapsing glomerulopathy can
be seen in association with human immunodeficiency
virus (HIV) infection but it has been increasingly rec-
ognized in non-HIV patients as well [2]. In 1986, Weiss
et al [1] reported six patients with rapidly progressive
nephrotic syndrome and glomerular capillary collapse.
Only one of the patients reported by Weiss subsequently
developed aquired immunodeficiency syndrome (AIDS)
and it was suggested that the rest of the patients could
present a new clinicopathologic entity. Pathologic fea-
tures were characterized by glomerular capillary collapse
and visceral epithelial cell swelling along with tubular cys-
tic dilatation and severe interstitial inflammatory changes
[1, 2]. Epidemiologic findings show a strong predom-
inance in the African American population [3]. Clini-
cal findings include severe nephrotic syndrome (usually
>10 g urinary protein in 24 hours), rapid progression to
ESRD or death due to complications of nephrotic syn-
drome [2]. In order to make the diagnosis of primary
collapsing glomerulopathy it is necessary to rule out the
presence of HIV infection since collapsing glomerulopa-
thy in HIV and non-HIV patients can be histopatholog-
ically indistinguishable [4]. Fifteen to fifty five percent
of the patients with focal segmental glomerulosclerosis
(FSGS) that undergo renal transplantation have recur-
rent disease [5, 6]. It has been suspected that circulating
factors can play a role in the pathogenesis of visceral ep-
ithelial cell damage in steroid-resistant minimal change
disease or recurrent FSGS [5]. Such factors are able to in-
duce functional alterations in the renal tissue in vitro [6]
and/or proteinuria in vivo when injected to the rat [5]. It
is well known that patients with collapsing glomerulopa-
thy present severe damage to the visceral epithelial cells
that cause heavy proteinuria, usually >10 g in 24 hours
[3]. Both recurrent and de novo collapsing glomeru-
lopathy have been described in the renal allograft with
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Table 1. Clinical characteristics of 10 patients with collapsing glomerulopathy
Characteristic, patient number 1 2 3 4 5 6 7 8 9 10
Age years 70 21 17 52 41 56 19 29 23 32
Gender F F F F M M M M M M
Blood pressure mm Hg 90/60 130/90 150/100 150/85 150/95 140/80 115/75 145/90 170/125 144/95
Serum creatinine mg/dL 1.6 7.3 2 1 0.8 2.9 0.9 1.53 1.7 1
Blood urea nitrogen mg/dL 15 25 24 22 9 29 14 32 32 18
Creatinine clearance mL/mina 29.6 5.8 25.5 47.6 96.3 26.4 105 54.2 37.1 82.6
Urinary protein g/day 15.00 10.00 14.00 12.00 12.70 10.00 11.00 10.00 12.30 14.00
Cholesterol mg/dL 269 134 418 341 362 246 213 363 239 226
Triglycerides mg/dL 103 162 737 181 452 327 120 243 107 132
Serum albumin g/day 1.9 0.9 1.4 2 2.1 4.6 3.4 4.3 1.6 3.3
aCreatinine clearance expressed in mL/min/1.73 m2 as calculated by the Levey method (Ann Intern Med 130:461–470, 1999).
Table 2. Pathologic findings in 10 patients with collapsing glomerulopathy
Patient number 1 2 3 4 5 6 7 8 9 10
Light microscopy
No. of glomeruli 18 20 20 12 11 16 10 18 23 20
Global collapse % 10 0 10 25 10 25 0 10 20 0
Segmental collapse % 0 20 20 0 10 0 25 20 10 25
Visceral epithelial cell hypertrophy damage % 100 100 80 100 100 100 100 100 100 100
Segmental sclerosis % 0 10 0 0 0 0 10 0 0 0
Global sclerosis % 0 10 0 0 0 0 0 0 0 10
Interstitial fibrosisa 0 I I 0 I I I II I II
Hyalinosis 0 0 0 0 0 0 0 0 0 0
Tubular atrophya 0 I I 0 I I I II I I
Tubular cystsb 0 0 0 0 0 0 0 I 0 I
Immunofluorescence microscopy Neg 1 + IgM Neg Neg Neg Neg Neg Neg 1 + IgM Neg
Electron microscopy ND EE FE EE EE EE ND EE FE EE
Abbreviations are: 1 + IgM, 1+/3+ mesangial deposition of IgM; ND, not done; EE, extensive visceral epithelial cell foot process effacement; FE, focal visceral
epithelial cell foot process effacement.
aScoring of interstitial fibrosis/atrophy 0, <10%; interstitial fibrosis/atrophy I, >10% <25% of cortical area; interstitial fibrosis/atrophy II, >25% <40% of cortical
area; interstitial fibrosis/atrophy III, >40% of cortical area.
bScoring of tubular cystic dilatation 0, negative; I, >10% <25% of cortical area.
histopathologic features similar to collapsing glomeru-
lopathy in a native kidney [7]. Recurrence of collapsing
glomerulopathy can occur hours after transplantation,
raising the possibility that the plasma of collapsing
glomerulopathy patients contains one or more factors
capable of inducing proteinuria due to the damage of
the visceral epithelial cell that results in the increase in
glomerular permeability [7].
To explore the possibility that humoral factors are in-
volved in the pathogenesis of the visceral epithelial cell
damage in collapsing glomerulopathy patients, we in-
jected serum and isolated IgG from patients with col-
lapsing glomerulopathy to Sprague-Dawley rats in order
to demonstrate that serum from patients with collaps-
ing glomerulopathy is capable of producing proteinuria
and ultrastructural changes in the visceral epithelial cells,
similar to those abnormalities seen in patients with col-
lapsing glomerulopathy, and compare it with serum from
noncollapsing FSGS patients.
METHODS
Study subjects
We obtained serum from ten patients with a clinical and
histopathologic diagnosis of collapsing glomerulopathy.
All patients had nephrotic syndrome with proteinuria >
10 g/24 hours. Polymerase chain reaction (PCR) for par-
vovirus B-19 (PVB-19) was negative in all patients. Renal
biopsy of patients with collapsing glomerulopathy pre-
sented characteristic glomerular capillary collapse, vis-
ceral epithelial cell swelling, and tubular damage. Direct
immunofluorescence was negative for immune-complex
deposition. Ultrastructural examination performed in all
patients demonstrated diffuse foot processes oblitera-
tion. Three to four glomeruli were analyzed per case.
Routinely, electron micrographs of five to six capillary
loops were review at 10,000 magnifications after a low
magnification of the whole glomerulus was performed.
Detailed clinical data and pathologic findings are showed
in Tables 1 and 2, respectively.
We also obtained serum from ten patients with
nephrotic syndrome with idiopathic noncollapsing FSGS.
All these patients fulfilled histopathologic criteria of
FSGS not otherwise specified (NOS) according to the
new pathologic classification of FSGS [8]. All biopsies
presented discrete peripheral (nonperihilar or tip lesion)
segmental consolidation of the glomerular tuft by in-
creased extracellular matrix, with at least one glomerulus
with segmental increase in matrix obliterating the capil-
lary lumina. Cases belonging to the morphologic variants
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Table 3. Clinical characteristics of 10 patients with focal segmental glomerulosclerosis (FSGS)
Characteristic, patient number 1 2 3 4 5 6 7 8 9 10
Age years 36 37 55 23 22 22 37 39 19 26
Gender M M M F F F F M M F
Blood pressure mm Hg 150/90 160/100 180/110 110/60 120/70 148/96 160/120 196/112 150/100 220/130
Serum creatinine mg/dL 2.2 1.5 1.2 2.5 0.7 2.5 2.5 1.5 3.0 0.9
Blood urea nitrogen mg/dL 27 22 22 32 18 19 27 22 29 16
Creatinine clearance mL/mina 37 52.4 59.3 25.5 71.4 26.9 23.5 56.7 29.6 81.1
Urinary protein g/day 5.7 8.3 3.4 3.0 6.0 3.5 3.1 3.0 5.4 3.1
Cholesterol mg/dL 202 273 260 270 645 269 287 272 283 297
Triglycerides mg/dL 195 202 184 260 685 305 282 252 208 154
Serum albumin g/dL 4.2 3.4 3.1 3.9 1.3 3.4 3.6 4.5 4 4.4
Treatment ACE P, ACE ACE ACE ACE ACE P, ACE P, ACE P, ACE P, ACE
Abbreviations are: P, pravastatine; ACE, angiotensin-converting enzyme inhibitor.
aCreatinine clearance expressed in mL/min/1.73 m2 as calculated by the Levey method (Ann Intern Med 130:461–470, 1999).
Table 4. Pathologic findings in 10 patients with focal segmental glomerulosclerosis (FSGS)
Patient number 1 2 3 4 5 6 7 8 9 10
Light microscopy
No. of glomeruli 8 18 29 7 15 10 6 11 18 14
Global collapse % 0 0 0 0 0 0 0 0 0 0
Segmental collapse % 0 0 0 0 0 0 0 0 0 0
Visceral epithelial cell prominence % 25 100 30 30 100 100 100 20 100 30
Segmental sclerosis % 20 30 30 10 30 20 10 10 30 20
Global sclerosis % 10 0 10 0 0 10 0 0 10 0
Interstitial fibrosisa I II II I II I I I I I
Hyalinosis % 20 20 30 0 10 0 0 0 20 0
Tubular atrophya I II II 0 I I I I I I
Tubular cystsb 0 0 0 0 0 0 0 0 0 0
Immunofluorescence microscopy Neg 1 + IgM Neg Neg Neg Neg Neg Neg 1 + IgM Neg
Electron microscopy ND EE FE EE EE EE ND EE FE EE
Abbreviations are: 1 + IgM, 1+/3+ mesangial deposition of IgM; ND, not done; EE, extensive visceral epithelial cell foot process effacement; FE, focal visceral
epithelial cell foot process effacement.
aScoring of interstitial fibrosis/atrophy 0, <10%; interstitial fibrosis/atrophy I, >10% <25% of cortical area; interstitial fibrosis/atrophy II, >25% <40% of cortical
area; interstitial fibrosis/atrophy III, >40% of cortical area.
bScoring of tubular cystic dilatation 0, negative; I, >10% <25% of cortical area.
with perihilar involvement, cellular variant, collapsing or
tip lesion were excluded. Electron microscopy examina-
tion was performed in all cases. Three to four glomeruli
were analyzed per case. Routinely, electron micrographs
of five to six capillary loops were review at 10,000 magni-
fication after a low magnification of the whole glomerulus
was performed. Detailed clinical data and histopatho-
logic findings are showed in Tables 3 and 4, respectively.
Serum from 12 healthy subjects from the Blood Bank,
matched by age and gender, was used as a control. Serums
of each group were pooled before fractionation.
Fractionation of serum
Purified IgG from serum of healthy subjects, FSGS,
and collapsing glomerulopathy patients was obtained by
the alcoholic precipitation method [9]. Serum without
IgG was obtained by fractionation with affinity-column
with protein A agarose (Bio-Rad, Hercules, CA, USA)
[5, 8, 9].
Polyacrylamide gel electrophoresis (PAGE) of the
proteins eluted from protein A
Proteins eluted from protein A agarose were re-
solved in sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) on SDS 5% to 8% gradient
PAGE [5]. Proteins were electrophoretically transferred
to nitrocellulose paper and immunoblotted against IgG to
assure the molecular weight of the purified IgG obtained
by both methods [10]. The protein bands and molecular
weight standards were stained with Coomassie blue.
Injection of serum and purified IgG into rats
Ninety-nine female Sprague-Dawley rats (250 to 280 g)
(Charles Rivers, Madison, WI, USA) were randomly dis-
tributed and placed in metabolic cages (Nalgene) with
water and food ad libitum. They were divided in 11 groups
(N = 9): group 1, as control, received no injections; group
2 received saline solution (NaCl 0.9%); group 3 was given
serum from healthy subjects, in its native form; group 4
received serum from collapsing glomerulopathy patients,
in its native form; group 5 was given serum from non-
collapsing FSGS patients, in its native form; group 6 re-
ceived serum from healthy subjects without IgG; group
7 received serum from collapsing glomerulopathy pa-
tients without IgG; group 8 was given serum from FSGS
without IgG; group 9 received purified IgG from healthy
subjects; group 10 received purified IgG from collapsing
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glomerulopathy patients; and group 11 was injected with
purified IgG from FSGS patients.
Serum was administered once intravenously, daily, in
the vein of the tail for 5 days in a concentration of
25 mg/mL in saline to a final volume of 1 mL, previous
sedation with ether in a narcosis chamber (Daigger).
Urine was collected every 24 hours for 6 days: prior the
first injection (baseline, day 0), and 24, 48, 72, 96, and 120
hours after the first injection (days 1 to 5, respectively).
Proteinuria was measured using the method of Biurett de-
scribed by Gornall, Bardawill, and David [11]. Urine of
day 5 was also used for urinary creatinine determination
by the method of Jaffe´ [12]. Rats were sacrificed 24 hours
after the last injection. Blood samples were taken for
creatinine determination in serum creatinine [12]. Left
kidney was obtained fresh and kept frozen for immuno-
histochemical analysis. Right kidney was perfused-fixed
in situ with a solution of 2% paraformaldehyde and 2.5%
glutaraldehyde in cacodylate buffer (pH 7.4) for light and
electron microscopy.
Histopathologic analysis
Rats were sacrificed 24 hours after the last injection.
Renal tissue was processed for light microscopy, direct
immunofluorescence, and electron microscopy, according
to standard techniques [13]. Sections for light microscopy
were stained with hematoxylin and eosin, periodic
acid-Schiff stain (PAS), Mallory trichrome stain and
Jones’ methenamine silver reaction. An average of 50
glomeruli per level of section in each sample was ex-
amined. All samples were evaluated for the presence of
glomerular collapse, mesangial expansion, and/or promi-
nence of the visceral epithelial cells. The presence of
immune deposits was evaluated by direct immunofluores-
cence. Frozen renal tissue was stained with FICT-bound
monoclonal antibodies against rat IgG (Caltag). Thirty
to thirty five glomeruli were examined per case. Fluores-
cence intensity was evaluated in a semiquantitative form
in a scale of 0 to 3+ (0, negative, 1+, weak, 2+, moderate,
and 3+, strong). Electron microscopy examination was
performed in all cases to look for the presence of tubu-
loreticular structures within the cytoplasm of endothe-
lial cells of glomerular capillary loops and capillaries of
the interstitium. Three to five glomeruli of each rat were
examined. At the ultrastructural level we also analyzed
wrinkling of the capillary loop basement membrane, vis-
ceral epithelial cell foot processes obliteration, and the
presence of droplets and vacuoles within the podocytes.
Renal biopsies were reviewed by an experienced renal
pathologist (M.C.A.C.). Evaluation of slides was blinded
to the observer.
Statistical analysis
The results of the protocol of injections of serum
and IgG from healthy subjects, not collapsing FSGS
and collapsing glomerulopathy patients are expressed as
the mean (±SD) of 24-hour proteinuria of groups of nine
rats during the 5 days of injection period and the base-
line (day 0). The statistical significance was calculated by
the t test (Sigma Plot Stat, version 2.1). P value was set
at <0.05, two-tailed.
RESULTS
Patients with collapsing glomerulopathy
Patients selected for the study fulfilled diagnostic crite-
ria for collapsing glomerulopathy [1]. All patients agreed
to participate in the study. Protocol was registered and ap-
proved by the Research and Ethics Review Board from
the hospital. All patients were Mexican, serology for HIV
was negative, and they denied contact with drugs. Patients
had primary disease without family history of renal dis-
ease. Six collapsing glomerulopathy patients were males
and four were females. Range of age varied from 17 to
70 years. At the time of diagnosis patients were hyper-
tensive (blood pressure mean 144 ± 28/95 ± 27 mm Hg).
Serum creatinine was increased in six patients and varied
from 0.8 to 7.3 mg/dL (2.03 ± 2 mg/dL). All collapsing
glomerulopathy patients presented massive proteinuria
with urinary protein excretion > 10 g/24 hours. Foot pro-
cesses effacement was confirmed by electron microscopy.
It was diffusely present in all but one patient. This patient
presented irregular foot process obliteration. Vacuoles
and blebs within podocytes in all biopsies were also iden-
tified. Serum samples were taken from 1 week to 1 month
after diagnosis was confirmed by a renal biopsy (Table 1).
Patients with FSGS
Patients selected had nephrotic syndrome (Table 3)
and a renal biopsy with diagnosis of noncollapsing FSGS
(NOS), according to the new pathologic classification for
the morphologic variants of FSGS [8]. All patients had
primary disease without family history of renal disease.
They were HIV negative and denied contact with drugs.
Five patients were males and five were females. Range of
age varied from 19 to 55 years. Eight out of 10 patients
were hypertensive at the time of diagnosis. Serum creati-
nine varied from 0.7 to 2.5 mg/dL. All patients presented
proteinuria in nephrotic ranges when serum samples were
taken (between 1 and 4 weeks after the renal biopsy).
Visceral epithelial foot process obliteration was present
in six patients while two have irregular effacement. The
presence of vacuoles and blebs within podocytes of all
patients were also analyzed.
Results of SDS-PAGE analysis of the protein
eluted from protein A
SDS-PAGE of the protein eluted from protein A and
of those obtained by alcoholic precipitation was used to
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Fig. 1. Results of sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) analysis of the protein eluted from protein A.
The first two columns show the isolated immunoglobulins from healthy
subjects (control) obtained by the alcoholic precipitation method. The
third column presents the serum of healthy subjects without IgG, af-
ter protein A agarose fractionation. The fourth and fifth columns show
isolated IgG from collapsing glomerulopathy (CG) patients obtained
by the alcoholic precipitation method. The sixth column shows the
serum of collapsing glomerulopathy patients without IgG, after pro-
tein A agarose fractionation. The seventh column shows a commercial
IgG (150 dD) marker and the ninth column is a commercial molecular
weight (MW) marker without IgG.
assess the molecular weight of the protein obtained by
such methods. The molecular weight of the protein ob-
tained by both methods, presumably IgG, corresponded
with the commercially available IgG (150 kD) as seen in
Figure 1.
Effects of the injection of total serum and IgG
from collapsing glomerulopathy patients, FSGS
patients, and healthy subjects on the renal function
and urinary protein excretion in rats
Results of the determination of urinary and serum cre-
atinine of each group were used to calculate the creati-
nine clearance in mL/min, to evaluate the renal function.
Results showed that rats receiving serum from collaps-
ing glomerulopathy patients had a significant decrease in
creatinine clearance compared with rats receiving serum
from healthy subjects or saline (P ≤ 0.0001). The group
of FSGS fractionated by agarose A affinity (group 8) had
a lesser, but significant, decrease in creatinine clearance
compared to the healthy subject rats (group 6) (P ≤ 0.05).
The rest of groups receiving FSGS did not show abnor-
malities in renal function. Results of creatinine clearance
values are shown in Table 5.
Urinary protein excretion in rats injected with serum
or isolated IgG from collapsing glomerulopathy patients
showed to be statistically significant (P = 0.0001 and
P ≤ 0.00001, respectively) compared with rats that re-
ceived serum from FSGS or healthy subjects (Table 6)
(Fig. 2), as follows. In group 1 (no injections), levels of
urinary protein excretion remained in the baseline (sim-
ilar to day 0), during the 5 days. In group 2 (injection
of saline), levels of urinary protein excretion remained
in the baseline during the 5 days of observation period.
Rats in group 3 (serum of healthy subjects) failed to de-
velop proteinuria during the 5 days of observation pe-
riod. Rats in group 4 (serum collapsing glomerulopathy)
presented proteinuria 24 hours after the first injection
(50.0 ± 6.3 mg/day) and the urinary protein excretion in-
creased to 99.2 ± 42 mg/24 hours at day 5, P = 0.0001,
compared to the baseline. In group 5 (serum FSGS), lev-
els of urinary protein excretion remained in the baseline
during the 5 days of observation period. Group 6 (serum
of healthy subjects without IgG) rats did not develop pro-
teinuria and urinary protein excretion remained in the
baseline at day 5. In group 7 (serum collapsing glomeru-
lopathy without IgG), rats developed mild proteinuria at
days 4 and 5 (30.9 ± 11) (P = 0.0001) compared to the
baseline. In group 8 (serum FSGS without IgG), no pro-
teinuria was found. Group 9 (isolated IgG from healthy
subjects) rats failed to develop proteinuria and urinary
protein excretion remained in the baseline. Group 10
(isolated IgG from collapsing glomerulopathy) rats de-
veloped mild proteinuria at day 3 with a light increase in
the urinary protein excretion at day 5 (46.5 ± 8.4) (P =
0.0001) compared to the baseline. Finally, group 11 (iso-
lated IgG from FSGS) rats did not develop proteinuria
and urinary protein excretion remained in the baseline at
day 5.
Histopathologic features
In group 1 (no injections), there were no abnormalities
either at light microscopy or electron microscopy exam-
ination (Fig. 3B). In group 2 (injection of saline), there
were no abnormalities either at light or ultrastructural
examination (Fig. 3C). In group 3 (serum of healthy sub-
jects), light and electron microscopy failed to show abnor-
malities in the glomeruli of rats (Fig. 3D). Group 4 (serum
collapsing glomerulopathy) rats injected with serum of
collapsing glomerulopathy patients showed retraction
of the glomerular tuft, visceral epithelial cell swelling,
and segmental collapse of the capillary loops (Fig. 3E).
Glomeruli appeared bigger than control. Electron mi-
croscopy demonstrated extensive foot processes oblit-
eration (Fig. 4A). Tubuloreticular structures were not
identified. There was slight tubular injury characterized
by changes in the cytoplasm that appeared eosinophilic,
and contained some vacuoles, especially around some
collapsed glomeruli. Nevertheless, brush border and nu-
clei were preserved. Group 5 (serum FSGS) rats were
without abnormalities at light and electron microscopy
(Fig. 3F). In group 6 (serum of healthy subjects without
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Table 5. Results of urinary creatinine excretion, serum creatinine values, and creatinine clearance calculation
Urinary creatinine Serum creatinine Creatinine clearance
Group Body weight mg/dL mg/dL mL/min
1 (control) 270 ± 1 g 1.4 × 10−4 ± 1.5 × 10−5 1.0 × 10−6 ± 4.0 × 10−7 1.29 ± 0.09
2 (saline) 277 ± 2 g 1.5 × 10−4 ± 3.6 × 10−5 1.1 × 10−6 ± 2.6 × 10−7 1.01 ± 0.33
3 (serum healthy subjects) 272 ± 2 g 1.5 × 10−5 ± 3.2 × 10−5 1.3 × 110−6 ± 4.1 × 10−7 0.77 ± 0.15
4 (serum collapsing glomerulopathy) 275 ± 2 g 9.5 × 10−5 ± 2.5 × 10−5 2.2 × 10−6 ± 5.9 × 10−7 0.32 ± 0.09a
5 (serum focal segmental glomerulosclerosis) 271 ± 1 g 2.3 × 10−4 ±1.0 × 10−5 1.3 × 10−6 ± 5.5 × 10−8 0.56 ± 0.07
6 (serum healthy subjects no IgG) 270 ± 1 g 1.9 × 10−4 ± 3.2 × 10−5 9.3 × 10−7 ± 2.1 × 10−7 1.55 ± 0.40
7 (serum collapsing glomerulopathy no IgG) 273 ± 1 g 1.1 × 10−4 ± 2.5 × 10−5 1.5 × 10−6 ± 2.3 × 10−7 0.68 ± 0.19a
8 (serum focal segmental glomerulosclerosis no IgG) 278 ± 3 g 1.2 × 10−4 ± 2.8 × 10−5 1.2 × 10−6 ± 0 0.86 ± 0.20b
9 (IgG healthy subjects) 275 ± 2 g 1.8 × 10−4 ± 3.0 × 10−5 1.4 × 10−6 ± 1.1 × 10−7 1.20 ± 0.68
10 (IgG collapsing glomerulopathy) 272 ± 1 g 1.1 × 10−4 ± 1.8 × 10−5 2.2 × 10−6 ± 3.7 × 10−7 0.43 ± 0.09b
11 (IgG focal segmental glomerulosclerosis) 275 ± 2 g 1.1 × 10−4 ± 2.5 × 10−5 1.1 × 10−6 ± 0 0.81 ± 0.21
aP ≤ 0.02 and bP ≤ 0.05 of collapsing glomerulopathy serum and focal segmental glomerulosclerosis serum versus healthy subjects. Results expressed in mean ± SD.
Table 6. Urinary protein daily excretion in the 11 groups of Sprague-Dawley ratsa
Baseline 24 hours 48 hours 72 hours 96 hours 120 hours
Group mg/day mg/day mg/day mg/day mg/day mg/day
1 (control) 6.0 ± 4.8 6.7 ± 4.7 3.9 ± 4.7 6.2 ± 3.3 5.0 ± 4.0 2.6 ± 3.4
2 (saline) 3.9 ± 3.5 5.6 ± 3.3 5.1 ± 3.03 5.4 ± 2.4 5.1 ± 3.2 5.0 ± 3.4
3 (S.HS) 5.3 ± 3.4 4.6 ± 2.9 5.8 ± 3.1 7.3 ± 3.9 9.1 ± 2.7 4.1 ± 3.1
4 (S CG) 13.5 ± 6.4 50.0 ± 6.3 57.0 ± 15 62.3 ± 16 90.5 ± 19 99.2 ± 42
5 (S FSGS) 0 0 4.6 ± 2.9 6.4 ± 0 16.9 ± 2 13.08 ± 0
6 (S HS no IgG) 0 0 0 3.9 ± 5.2 6.2 ± 6.1 7.2 ± 6.1
7 (S CG no IgG) 8.8 ± 7.3 16.8 ± 12 17.1 ± 11 25.4 ± 7.4 30.5 ± 4.3 30.9 ± 11
8 (S FSGS no IgG) 0 0 0 2.9 ± 3.3 11.5 ± 13 11.5 ± 11
9 (IgG CG) 0 11.3 ± 3.9 26.0 ± 3.4 38.7 ± 5.8 42.7 ± 9.2 46.5 ± 8.4
10(IgG HS) 4.6 ± 4.9 4.5 ± 4.3 5.8 ± 5.5 5.4 ± 5.4 0 0
11(IgG FSGS) 0 0 0 0 0 8.0 ± 9.3
Abbreviations are: S.HS, serum healthy subjects; S GC, serum collapsing glomerulopathy; S.HS no IgG, serum of healthy subjects without IgG; S. CG no IgG, serum
of collapsing glomerulopathy without IgG, IgG HS, isolated IgG of healthy subjects; IgG CG, isolated IgG of collapsing glomerulopathy; IgG FSGS, isolated IgG of
focal segmental glomerulosclerosis.
aMean ± SD.
IgG), there were no abnormalities at light or electron mi-
croscopy (Fig. 3G). Group 7 (serum collapsing glomeru-
lopathy without IgG) rats showed prominence of vis-
ceral epithelial cells and segmental capillary retraction.
No tubular damage was found. Ultrastructural examina-
tion demonstrated foot processes obliteration (Fig. 3H).
In group 8 (serum FSGS without IgG), there were no
glomeruli abnormalities at light or electron microscopy
(Fig. 3I). Group 9 (isolated IgG of healthy subjects) rats
showed no abnormalities at light or electron microscopy
(Fig. 3J). Group 10 (isolated IgG collapsing glomeru-
lopathy) rats injected with isolated IgG from patients
with collapsing glomerulopathy showed retraction of the
glomerular tuft with prominence of the visceral epithe-
lial cells (Fig. 3K). Tubular damage around retracted
glomeruli was not identified. Ultrastructural examination
demonstrated irregular foot process obliteration. Tubu-
loreticular structures were not found. Finally, in group 11
(isolated IgG from FSGS), there were no abnormalities
at light or electron microscopy (Fig. 3L). Visceral epithe-
lial cell foot process obliteration of groups injected with
collapsing glomerulopathy serum is showed in Figure 4
(Table 7).
Direct immunofluorescence against rat IgG was nega-
tive for the presence of immune-complex in all groups.
Linear IgG against glomerular basemen membrane
was seen in groups receiving collapsing glomerulopathy
serum (groups 4, 7, and 10) (data not shown).
DISCUSSION
In the present study we injected serum from pa-
tients with clinical and pathologic diagnosis of collapsing
glomerulopathy to Sprague-Dawley rats in order to study
the effect of the injection on the production of protein-
uria and histopathologic damage, in vivo, compared with
the injection of serum from FSGS patients and healthy
subjects. Serum was administered in one of three forms:
(1) in its native form (nonadsorbed), (2) only the isolated
IgG obtained by alcoholic precipitation method, and (3)
serum without IgG (extracted by chromatography with
protein A agarose). Results showed clearly that the in-
jection of serum of collapsing glomerulopathy patients to
Sprague-Dawley rats in any of these three forms induces
proteinuria and visceral epithelial cell damage.
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Fig. 2. Urinary protein excretion in rats.
Graph 1 shows urinary protein excretion of
rats of groups 1 (no injections) and 2 (in-
jections of saline), remained in the baseline
(<10 mg/day) during the 5 days of observation
period. Graph 2 compares the urinary protein
excretion between groups 3 and 4 and group 5.
While urinary protein excretion of rats receiv-
ing serum of healthy subjects and focal segmal
glomerulosclerosis (FSGS) in its native form
(groups 3 and 5) remains in the baseline, rats
receiving serum of collapsing glomerulopathy
patients in its native form (group 4) present
proteinuria 24 hours after the first injection
(50.0 ± 6.3 mg/day) and finally to 99.2 ±
42 mg/24 hours at day 5 (∗∗P = 0.0001 com-
pared to its baseline). Graph 3 shows rats of
groups 6 (serum of healthy subjects without
IgG) and 8 (serum from FSGS without IgG)
did not develop proteinuria and urinary pro-
tein excretion remained in the baseline at day
5. Rats of group 7, (serum collapsing glomeru-
lopathy without IgG) developed proteinuria
24 hours after the first injection and mild pro-
teinuria was reached at days 4 and 5 (30.9 ±
11) (∗∗P = 0.0001 compared to its baseline).
Graph 4 shows rats of groups 9 (isolated IgG
of healthy subject) and 11 (isolated IgG of
FSGS) failed to develop proteinuria at day
5 compared to rats of group 10, (isolated
IgG of collapsing glomerulopathy) that devel-
oped mild proteinuria at day 3 with a light in-
crease in the urinary protein excretion at day 5
(46.5 ± 8.4) (∗∗P = 0.0001 compared to its
baseline).
It has been proposed that patients with damage to
the visceral epithelial cell with a pattern of minimal
change disease and FSGS with recurrence of nephrotic
syndrome in the allograft could present a circulating fac-
tor responsible for the production of proteinuria [5, 6,
14, 15]. An elegant in vitro study has demonstrated that
some circulating factors present in patients with FSGS
can produce changes in glomerular permeability when
isolated glomeruli are incubated with the serum of the
patients [14]. Another study has demonstrated that a
factor present in the plasma of FSGS patients increases
glomerular permeability in vitro and causes transient pro-
teinuria in vivo [15, 16]. However, up to now, there are
no in vivo studies clearly demonstrating the evidence of
histopathologic damage to the visceral epithelial cell sec-
ondary to the presence of circulating factors exclusively
in collapsing glomerulopathy. To support the evidence
of a circulating factor present in patients with collapsing
glomerulopathy it has been pointed out that collapsing
glomerulopathy can recur rapidly after transplantation
[15]. Reported time for recurrence in the allograft varies
between 4 and 26 weeks [15, 16], based on the presence of
proteinuria, although this fact depends also on the time
performance of the biopsy since some reports have found
recurrence of the disease as far as 144 months after trans-
plantation, when a renal allograft biopsy has been per-
formed [7]. The hypothesis of circulating factors has also
been supported by the observation that plasmapheresis
and plasma protein adsorption onto a protein A column
often decrease urinary protein excretion in patients with
recurrent idiopathic nephrotic syndrome [16, 17]. The ef-
fect on the urinary protein excretion is only transient
and after some weeks patients may have recurrence of
the symptoms [5, 16]. Therefore, the possibility that pa-
tients with recurrent FSGS have circulating factors that
are capable to alter glomerular permeability to macro-
molecules has been suggested repeatedly by different
authors [2, 5, 6, 14, 16].
Studies in the utility of plasmapheresis in the treatment
of recurrent FSGS have shown that this method reduces
proteinuria and glomerular injury [17]. In the former
study, plasmapheresis reduced proteinuria from a mean
of 12 ± 7.46 g/24 hours to 5.1 ± 7.43 g/24 hours [17]. The
demonstration of circulating factors in the pathogenesis
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Fig. 3. Histopathologic features. (A) Light microscopy of a patient with diagnosis of collapsing glomerulopathy. Retraction and collapse of the
glomerular tuft is seen. Visceral epithelial cells appear hypertrophied in the urinary space (periodic acid-Schiff stain 400×). (B) Group 1 (no
injections). No abnormalities are seen at light microscopy. Capillary loops are open (periodic acid-Schiff stain 600×). (C) Group 2 (injection of
saline). No abnormalities are seen at light microscopy. Capillary loops are open (periodic acid-Schiff stain, 600×). (D) Group 3 (serum of healthy
subjects). Light microscopy failed to show abnormalities in the glomeruli of rats belonging this group. Capillary loops are open and capillary loops
basement membranes are fine and delicate. Visceral epithelial cells are not appreciated (periodic acid-Schiff stain, 600×). (E) Group 4 (serum
collapsing glomerulopathy patients). Glomerulus is large. Global retraction of the glomerular tuft, visceral epithelial cell swelling and collapse
of the capillary loop are appreciated (periodic acid-Schiff stain, 600×). (F) Group 5 [serum focal segmental glomerulosclerosis (FSGS) patients].
Glomerulus appears normocelular, capillary loops are open. Visceral epithelial cells are not appreciated (periodic acid-Schiff stain, 600×). (G)
Group 6 (serum of healthy subjects without IgG). No abnormalities at light microscopy are present in this group (periodic acid-Schiff stain, 600×).
(H) Group 7 (serum collapsing glomerulopathy without IgG). Glomerulus is large. Prominence of visceral epithelial cells and segmental capillary
retraction are present in this rats. Although brush border is preserved, some vacuoles are seen within tubular cells (periodic acid-Schiff stain, 600×).
(I) Group 8 (serum FSGS without IgG). Capillary loops are open, no abnormalities are seen by light microscopy (periodic acid-Schiff stain, 600×).
(J) IgG of healthy subjects. No abnormalities at light microscopy were found in this group. Capillary loops are open (periodic acid-Schiff stain,
600×). (K) Isolated IgG collapsing glomerulopathy. Glomerulus is large. Partial retraction of the glomerular tuft with prominence of the visceral
epithelial cells (periodic acid-Schiff stain, 600×). (L) Isolated IgG FSGS. Capillary loops are open (periodic acid-Schiff stain, 600×).
of the glomerular damage in collapsing glomerulopathy
would be very useful, since treatments like plasmaphere-
sis could help not only to reduce proteinuria but, if such
treatment is initiated early after diagnosis, patients could
also have lasting remissions.
Although there has been no evidence of the involve-
ment of immunoglobulins in the pathogenesis of collaps-
ing glomerulopathy, some studies have proposed that IgG
could have a role in the production of proteinuria in recur-
rent nephrotic syndrome in FSGS [5]. These studies have
demonstrated a decrease in urinary protein excretion in
patients with recurrent nephrotic syndrome after protein
adsorption with protein A. It is well known that protein A
binds the constant domains of some immunoglobulins [5].
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Fig. 4. Electron micrographs. (A) Ultrastructural examination of rat of group 4 (serum collapsing glomerulopathy) showing extensive foot process
obliteration (20,000×). (B) Capillary loop of rat of group 7 showing irregular visceral epithelial cell foot process effacement (20,000×). (C) Capillary
loop of rat of group 10 showing irregular foot process effacement (6300×).
In the present study, rats injected with purified IgG from
patients with collapsing glomerulopathy (group 10) de-
veloped mild proteinuria (46.5 ± 8.4 mg/day), compared
with those rats injected with serum from patients with col-
lapsing glomerulopathy in its native form (group 4) that
presented heavy proteinuria at day 5 (99.2 ± 42 mg/day).
What is more, rats injected with serum from patients with
collapsing glomerulopathy without IgG (group 7), also
presented mild proteinuria (30.9 ± 11 mg/day). This ob-
servation may suggest that the factors responsible for the
production of proteinuria are not only bound to the IgG,
and that those other factors present in the rest of the
serum may also play an important role in the produc-
tion of proteinuria. It can also stress the fact that there is
more than one factor responsible for the alteration of the
glomerular permeability, and that the administration of
all factors together in the serum in its native form, as seen
in rats of group 4, produces more proteinuria than when
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Table 7. Histopathologic findings in 11 groups
Group 1 2 3 4 5 6 7 8 9 10 11
Light microscopy
No. of glomeruli 120 137 143 144 130 123 140 144 150 138 130
Global retraction % 0 0 0 25 0 0 20 0 0 20 0
Segmental collapse % 0 0 0 20 0 0 20 0 0 20 0
Visceral epithelial cell prominence % 0 0 0 50 0 0 30 0 0 25 0
Segmental sclerosis % 0 0 0 0 0 0 0 0 0 0 0
Global sclerosis % 0 0 0 0 0 0 0 0 0 0 0
Interstitial fibrosisa 0 0 0 0 0 0 0 0 0 0 0
Tubular necrosis 0 0 0 0 0 0 0 0 0 0 0
Immunofluorescence Neg Neg Neg Neg, linear Neg Neg Neg, linear Neg Neg Neg, linear Neg
Electron microscopy N N N EE N N FE 0 0 FE N
Abbreviations are: N, normal; EE, extensive visceral epithelial cell foot process effacement; FE, focal and irregular visceral epithelial cell foot process effacement.
No. of glomeruli represents the average of glomeruli per section. Glomerular damage was present only in rats receiving serum from CG patients.
those factors are administered individually (groups 7 and
11). It has been found that protein A eluates contain not
only immunoglobulin but also other proteins [5]. Proteins
eluted from protein A agarose were analyzed by SDS-
PAGE [5] on 5% to 10% polyacrylamide gradient gels
under reducing and nonreducing conditions to assure the
molecular weight of the purified IgG. Immunoblotting
of these gels showed a band of protein identical to the
band of commercial IgG, used as a control, and we did
not find evidence of other bands of proteins. It is impor-
tant to stress out the fact that our groups injected with
serum from patients with noncollapsing FSGS (groups 5,
8, and 11) did not develop proteinuria or visceral epithe-
lial cell damage by light or electron microscopy. Studies
demonstrating the presence of circulating factors in pa-
tients with nephrotic syndrome or recurrent nephrotic
syndrome in the allograft were performed in patients
diagnosed as steroid resistant FSGF or recurrent FSGS
[5]. Several of those studies show minimal or no depic-
tion of the cases from which serum was derived, neither
the morphologic variant of FSGS, especially if collapsed
glomeruli were present in the biopsy [5, 16–18]. In the
present study we utilized serum only from prospectively
selected patients with noncollapsing FSGS classified as
FSGS (NOS) according to the recently proposed classifi-
cation for the morphologic variants of FSGS [8]. All pa-
tients had nephrotic range proteinuria by the time serum
samples were taken. Many other studies showing perme-
ability factors in FSGS have been performed in vitro and
not as in vivo assay [16]. Therefore, another explanation
could be that noncollapsing FSGS patients have different
factors that collapsing glomerulopathy patients and they
could be weakened by degradation when administrated
to the rat by intravenous injection in the vein of the tail,
resulting in an absence of response. Another important
possibility to point out is that data are real and there are
only certain morphologic variants of FSGS with circulat-
ing factors that alter the glomerular filtration.
The histopathologic features of the different groups
of rats showed clearly the presence of visceral epithe-
lial cell damage in all rats receiving serum from patients
with collapsing glomerulopathy compared with those re-
ceiving serum from FSGS or healthy subjects. There was
no difference in the type of damage between all groups
that received serum from collapsing glomerulopathy pa-
tient (groups 4, 7, and 11), but in group 4 (serum of
collapsing glomerulopathy patients in its native form)
there was extensive foot processes obliteration by elec-
tron microscopy; this correlates with major proteinuria
in this group. It is interesting that glomeruli of collapsing
glomerulopathy rats in all groups appear diffusely bigger
than controls. Although there was no striking damage
to the tubules, eosinophilia in proximal tubules, espe-
cially those surrounding some collapsed glomeruli, was
identified. This change could be the result of tubular dam-
age due to proteinuria since droplets of albumin can be
observed in these areas. Light microscopy of all rats in-
jected with collapsing glomerulopathy sera had some re-
traction of the glomerular tuft but we did not find marked
glomerular collapse and droplets within the visceral ep-
ithelial cells. The presence of wrinkling of the glomeru-
lar basement membrane or tubuloreticular structures in
the endothelium of the capillary loops were not found
by electron microscopy examination in any of the cases.
Therefore, differing from noncollapsing FSGS rats, an-
imals injected with serum from patients with collapsing
glomerulopathy developed a characteristic damage of the
visceral epithelial cells and proteinuria, as seen in collaps-
ing glomerulopathy patients. One important point is that
in all previous reported studies there is a lack of rela-
tion between the specific morphologic type of visceral
epithelial cell disease and the plasma factors implicated,
since the morphologic and clinical characteristics of the
patients are not provided and they are all included un-
der the term recurrent FSGF or recurrent nephrotic syn-
drome [14, 19–21]. Our study was performed with sera of
patients with clinical and pathologic diagnosis of primary
collapsing glomerulopathy, exclusively, versus sera from
patients with noncollapsing FSGS.
The precise characterization of the biochemical proper-
ties and nature of the circulating factors implicated in the
development of glomerular damage and proteinuria in
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collapsing glomerulopathy will need further studies. An
inconsistent proteinuria following the injection of FSGS
sera into experimental animals has been attributed to
factors present in normal serum that block the perme-
ability effect of active FSGS sera [20]. Although differ-
ent studies on the characterization of plasma factors has
been performed [13, 19–21], at the present time, the pre-
cise nature of the active factors remains speculative [22].
As a consequence, the relationship between the perme-
ability factor and glomerular capillary collapse and scar-
ring has not been clarified. We have enough evidence
to support the fact of the presence of circulating fac-
tors that produce proteinuria and visceral epithelial dam-
age in collapsing glomerulopathy patients. Differing from
collapsing glomerulopathy, serum from noncollapsing
FSGS did not produce visceral epithelial cell damage
when injected to the rat raising the possibility that perme-
ability substances in plasma of FSGS patients are present
only in certain variants of this striking disease.
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